Cantor Fitzgerald Forecasts ALX Oncology FY2025 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ALX Oncology in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek forecasts that the company will post earnings per share of ($2.21) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ALX Oncology’s current full-year earnings is ($2.76) per share.

Other research analysts have also recently issued research reports about the company. HC Wainwright lowered their price objective on ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday. Jefferies Financial Group lowered shares of ALX Oncology from a “buy” rating to a “hold” rating and lowered their price target for the stock from $12.00 to $2.00 in a research report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $3.50.

ALX Oncology Stock Performance

NASDAQ:ALXO opened at $1.52 on Thursday. The stock has a 50 day simple moving average of $1.61 and a 200 day simple moving average of $2.42. The stock has a market cap of $79.90 million, a P/E ratio of -0.51 and a beta of 0.98. ALX Oncology has a 1-year low of $1.19 and a 1-year high of $17.83. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07.

Insider Activity

In other news, Director Rekha Hemrajani bought 30,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was bought at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the transaction, the director now owns 33,000 shares of the company’s stock, valued at $51,150. This represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 14,443 shares of company stock worth $23,309. 33.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its holdings in shares of ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock valued at $333,000 after purchasing an additional 5,360 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of ALX Oncology by 87.2% during the 2nd quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock worth $2,642,000 after buying an additional 204,100 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in ALX Oncology in the second quarter valued at about $63,000. Marshall Wace LLP raised its stake in ALX Oncology by 423.0% during the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after acquiring an additional 514,133 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of ALX Oncology in the second quarter worth about $1,203,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.